In simple terms, Aptevo Therapeutics Inc. has 11.524 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 10.084%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -8.396%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.904% return, is a testament to Aptevo Therapeutics Inc.'s adeptness in optimizing resource deployment. Aptevo Therapeutics Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.428%. Furthermore, the proficiency of Aptevo Therapeutics Inc. in capital utilization is underscored by a remarkable -1.427% return on capital employed.
Stock Prices
Aptevo Therapeutics Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.492, while its low point bottomed out at $0.41. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Aptevo Therapeutics Inc.'s stock market.
Company general description and statistics
Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Marvin L. White
Full-time employees:45
City:Seattle
Address:2401 4th Avenue
IPO:2016-07-20
CIK:0001671584
Website:
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
